Subscribe or Manage Preferences

ASH 2014 - CLL

Listen as Dr. Jennifer Brown provides her views on precision vs personalized medicine in CLL
In this segment Dr. Jennifer Brown touches on the importance of combination therapy and the importance of designing studies with novel/novel agents.
Dr. Jennifer Brown discuss the approval of new drugs and the data around these drugs for CLL
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the standard first-line therapy for CLL based on the results of the CLL8 study, which showed improved PFS and OS with FCR versus fludarabine plus cyclophosphamide (FC)...
Page 1 of 3
Results 1 - 10 of 24
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology